Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1955 1
1956 1
1957 1
1960 2
1962 1
1963 1
1964 2
1966 4
1967 2
1968 2
1969 1
1972 3
1973 1
1974 1
1975 1
1976 4
1977 1
1978 2
1979 1
1980 4
1981 2
1983 7
1984 11
1985 7
1986 7
1987 11
1988 7
1989 19
1990 16
1991 19
1992 26
1993 17
1994 13
1995 21
1996 24
1997 28
1998 35
1999 34
2000 35
2001 37
2002 28
2003 36
2004 43
2005 59
2006 54
2007 70
2008 53
2009 71
2010 71
2011 91
2012 84
2013 106
2014 116
2015 112
2016 127
2017 137
2018 156
2019 160
2020 219
2021 213
2022 218
2023 201
2024 82

Text availability

Article attribute

Article type

Publication date

Search Results

2,596 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients.
Molica M, Perrone S, Rossi M. Molica M, et al. Among authors: rossi m. J Clin Med. 2023 May 24;12(11):3647. doi: 10.3390/jcm12113647. J Clin Med. 2023. PMID: 37297842 Free PMC article. Review.
Moreover, the phase I/II dose-escalation, dose-expansion Chrysalis trial showed an acceptable safety profile of gilteritinib (diarrhea, elevated aspartate aminotransferase, febrile neutropenia, anemia, thrombocytopenia, sepsis, and pneumonia) and a 49% overall response rate (ORR) …
Moreover, the phase I/II dose-escalation, dose-expansion Chrysalis trial showed an acceptable safety profile of gilteritinib (diarrhea, elev …
Uncommon Complications after Anterior Cruciate Ligament Reconstruction.
Palazzolo A, Rosso F, Bonasia DE, Saccia F, Rossi R; Knee Committee SIGASCOT. Palazzolo A, et al. Among authors: rossi r. Joints. 2018 Nov 30;6(3):188-203. doi: 10.1055/s-0038-1675799. eCollection 2018 Sep. Joints. 2018. PMID: 30582108 Free PMC article. Review.
Anterior cruciate ligament reconstruction (ACL-R) is a common surgical procedure, with good outcome in 75 to 97% of the cases. ...The aim of this paper is to review the literature describing uncommon complications after ACL-R, giving some more information about diag …
Anterior cruciate ligament reconstruction (ACL-R) is a common surgical procedure, with good outcome in 75 to 97% of the cases. ...The …
Finding Maximal Exact Matches Using the r-Index.
Rossi M, Oliva M, Bonizzoni P, Langmead B, Gagie T, Boucher C. Rossi M, et al. J Comput Biol. 2022 Feb;29(2):188-194. doi: 10.1089/cmb.2021.0445. Epub 2022 Jan 17. J Comput Biol. 2022. PMID: 35041518 Free PMC article.
But until recently, it was unknown how to build a data structure in [Formula: see text] space that supports efficient MEM finding, where r is the number of runs in the Burrows-Wheeler Transform. In 2021, Rossi et al. showed how to build a small auxiliary data structure cal …
But until recently, it was unknown how to build a data structure in [Formula: see text] space that supports efficient MEM finding, where …
Efficient taxa identification using a pangenome index.
Ahmed O, Rossi M, Boucher C, Langmead B. Ahmed O, et al. Among authors: rossi m. Genome Res. 2023 Jul;33(7):1069-1077. doi: 10.1101/gr.277642.123. Epub 2023 May 31. Genome Res. 2023. PMID: 37258301 Free PMC article.
Tools that classify sequencing reads against a database of reference sequences require efficient index data-structures. The r-index is a compressed full-text index that answers substring presence/absence, count, and locate queries in space proportional to the amount of dis …
Tools that classify sequencing reads against a database of reference sequences require efficient index data-structures. The r-index i …
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
Calabretta E, di Trani M, Corrado F, Sollini M, Cristaldi V, Marino F, Terzi di Bergamo L, Bruscaggin A, Pirosa MC, Bramanti S, Chiti A, Rossi D, Carlo-Stella C. Calabretta E, et al. Among authors: rossi d. Br J Haematol. 2024 Feb;204(2):514-524. doi: 10.1111/bjh.19162. Epub 2023 Oct 18. Br J Haematol. 2024. PMID: 37853658
Reliable biomarkers for early identification of treatment failure in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL) are lacking. Circulating tumour DNA (ctDNA) profiling has emerged as a powerful predictive and prognostic tool in several haemopoietic and …
Reliable biomarkers for early identification of treatment failure in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL …
Non-Coding RNAs and Splicing Activity in Testicular Germ Cell Tumors.
Barchi M, Bielli P, Dolci S, Rossi P, Grimaldi P. Barchi M, et al. Among authors: rossi p. Life (Basel). 2021 Jul 24;11(8):736. doi: 10.3390/life11080736. Life (Basel). 2021. PMID: 34440480 Free PMC article. Review.
Here, we summarize how the different expression of RNA species repertoire, including non-coding RNAs and protein-coding splicing variants, impacts on TGCTs' onset and progression and sustains therapeutic resistance. Finally, the role of transcription-associated R-loop misr …
Here, we summarize how the different expression of RNA species repertoire, including non-coding RNAs and protein-coding splicing variants, i …
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.
Meijer L, Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. Meijer L, et al. Among authors: rossi ag. J Innate Immun. 2016;8(4):330-49. doi: 10.1159/000444256. Epub 2016 Mar 18. J Innate Immun. 2016. PMID: 26987072 Free PMC article. Review.
(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine a …
(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatmen …
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, Debureaux PE, Cavalieri D, Fornecker LM, Casasnovas RO, Herbaux C, Amorim S, Rossi C, Bouscary D, Brice P, Ghesquieres H, Tamburini J, Deau B. Marouf A, et al. Among authors: rossi c. Br J Haematol. 2023 Jul;202(2):379-383. doi: 10.1111/bjh.18859. Epub 2023 May 16. Br J Haematol. 2023. PMID: 37192755
Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high-risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV-naive …
Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high-risk relapsed/refractory Hodg …
Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update.
Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M, Dolan O'Brien M, Eliashiv DS, Erten-Lyons D, Giesser BS, Moo LR, Narayanaswami P, Rossi MA, Soni M, Tariq N, Tsao JW, Vargas BB, Vota SA, Wessels SR, Planalp H, Govindarajan R. Hatcher-Martin JM, et al. Among authors: rossi ma. Neurology. 2020 Jan 7;94(1):30-38. doi: 10.1212/WNL.0000000000008708. Epub 2019 Dec 4. Neurology. 2020. PMID: 31801829 Review.
2,596 results